Fred Saad, MD (he/him/his)

Professor and Chairman Department of Surgery
University of Montreal Hospital Center

Fred Saad is Professor and Chairman of the Department of Surgery at the Université de Montréal and holds the Raymond Garneau Chair in Prostate Cancer Research. He is Director of GU Oncology and the Molecular Oncology Research Laboratory in Prostate Cancer. His research interests include novel therapeutics in prostate cancer, molecular prognostic markers, and mechanisms of progression. He has over 40 clinical and basic research projects ongoing and has received over 50 million in research grants. Prof. Saad currently sits on over 15 steering committees of international clinical trials and serves on several guideline committees.

He has played a leadership role in most of the practice-changing clinical trials and publications in advanced prostate cancer over the last 25 years. He is a member of several editorial boards, including Lancet Oncology, JAMA Oncology and Nature Urology. He has over 1100 peer-reviewed publications, a h-index of 160 and over 150,000 citations and is listed as one of the world’s most-cited scientists. Dr Saad has held several leadership positions including President of the Canadian Urologic Association (CUA), the Quebec Urological Association (QUA), the NCI of Canada GU-group and the Canadian Uro-Oncology Group. He is the recipient of numerous awards including Lifetime Achievement Awards from the CUA and QUA and the Distinguished Contribution Award from the AUA. He is a Fellow of the Canadian Academy of Health Sciences and the American Association of GU Surgeons and was named a Knight of The National Order of Quebec, the highest honour given by the Government of Quebec.

Disclosure information not submitted.

Presentation(s):

• MP11-16: Prostate-specific antigen analyses in PROpel: abiraterone and olaparib versus abiraterone and placebo as first-line therapy for metastatic castration-resistant prostate cancer

  Friday, April 28, 2023
  9:30 AM – 11:30 AM CST

• MP29-01: Rapid, Durable, and Deep Prostate-Specific Antigen Response Following Addition of Darolutamide to Androgen-Deprivation Therapy and Docetaxel in ARASENS

  Saturday, April 29, 2023
  7:00 AM – 9:00 AM CST

• Metastatic Castration Resistant Prostate Cancer: Efficacy, Toxicity and Indication of PARP Inhibitors

  Saturday, April 29, 2023
  1:45 PM – 2:05 PM CST

• Panel Time: Metastatic Castrate Sensitive Prostate Cancer

  Sunday, April 30, 2023
  11:55 AM – 12:05 PM CST

• Second Update: Is Combination Therapy the New Standard of Care for Metastatic Castrate Resistant Prostate Cancer Patients?

  Sunday, April 30, 2023
  12:05 PM – 12:15 PM CST

• Panel Time: Metastatic Castrate Resistant Prostate Cancer

  Sunday, April 30, 2023
  12:15 PM – 12:25 PM CST

• Panel Time: Cases in Prostate Cancer Theranostics

  Sunday, April 30, 2023
  12:35 PM – 12:45 PM CST

• Beyond The Guidelines: Urologic Oncology Investigators Provide Perspectives on the Optimal Management of Prostate Cancer

  Sunday, April 30, 2023
  5:30 PM – 8:00 PM CST